Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of “Moderate Buy” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $423.00.

Several equities analysts have recently issued reports on MEDP shares. Mizuho initiated coverage on Medpace in a research report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price target on the stock. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Thursday, September 5th. William Blair reissued an “outperform” rating on shares of Medpace in a research note on Wednesday, September 11th. TD Cowen lowered their price objective on shares of Medpace from $452.00 to $434.00 and set a “buy” rating on the stock in a research note on Wednesday, July 24th. Finally, Guggenheim dropped their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a report on Wednesday, July 24th.

Medpace Stock Up 2.0 %

MEDP stock opened at $351.67 on Monday. The company has a 50-day simple moving average of $384.27 and a 200 day simple moving average of $393.30. The company has a market capitalization of $10.90 billion, a P/E ratio of 35.85, a PEG ratio of 1.74 and a beta of 1.35. Medpace has a fifty-two week low of $227.21 and a fifty-two week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. During the same period in the prior year, the business posted $1.93 EPS. The business’s revenue for the quarter was up 14.6% compared to the same quarter last year. Equities analysts anticipate that Medpace will post 11.66 EPS for the current year.

Institutional Investors Weigh In On Medpace

Large investors have recently made changes to their positions in the company. Rise Advisors LLC acquired a new position in Medpace in the 1st quarter worth approximately $27,000. Mather Group LLC. purchased a new stake in shares of Medpace in the first quarter valued at $28,000. Fidelis Capital Partners LLC acquired a new stake in shares of Medpace in the first quarter worth $31,000. J.Safra Asset Management Corp boosted its position in shares of Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after buying an additional 47 shares during the period. Finally, DT Investment Partners LLC acquired a new position in Medpace during the second quarter valued at $41,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.